SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
Acquisitions · S-4
Mergers & Acquisitions
M&A Details · Industry · Urgent
M&A Deals · Breakdown
SpringWorks Therapeutics, Inc. has no acquisition track records yet.
M&A Deals · History
SpringWorks Therapeutics, Inc. has no acquisition track records yet.
SpringWorks Therapeutics, Inc. can't present any M&A detail analysis.
Try it with one of the Urgent M&A Deals by clicking "Details".
Try it with one of the Urgent M&A Deals by clicking "Details".
M&A Deals · Within Industry
Keep an eye on latest M&A deals done inside the Biotechnology Industry.
M&A Deals · Urgent
Act, dont react; Track the most urgent M&A deals across all industries
Details
Details
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
Details
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00